(P036) Patterns of Care and Outcomes of Adjuvant Radiotherapy for Meningiomas: A Surveillance, Epidemiology, and End Results and Medicare-Linked Analysis

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Utilization of adjuvant XRT and SRS remained stable between 2000 and 2010. Male sex, young age, marriage, partial resection, grade II/III tumors, and large tumors predicted for use of adjuvant therapy. For all patients, SRS improved survival compared with craniotomy alone. For patients with incomplete resection, SRS improved survival compared with craniotomy alone and adjuvant XRT. Randomized, prospective clinical trials are needed to better define the role of adjuvant XRT or SRS.

Mark J. Amsbaugh, MD, Beatrice Ugiliweneza, PhD, MSPH, Eric Burton, MD, Maxwell Boakye, MD, MPH, MBA, Shiao Woo, MD; University of Louisville

PURPOSE: To identify patterns of care and outcomes of adjuvant radiotherapy for meningiomas in the linked Surveillance, Epidemiology, and End Results (SEER) Medicare data.

MATERIALS AND METHODS: Patients over 66 years of age, diagnosed with meningioma, and treated with a craniotomy in the SEER-Medicare data were included. Patients were grouped according to adjuvant treatment with fractionated radiotherapy (XRT), stereotactic radiosurgery (SRS), or none. Demographic, tumor, treatment, and outcome variables were collected. The Mann-Whitney U-test and chi-square test were used to analyze continuous and categorical variables. Time to event was analyzed with the Kaplan-Meier methods and log-rank test. Multivariate comparisons were conducted with logistic regression and proportional hazard models.

RESULTS: A total of 1,964 patients were included for analysis (1,701 with no adjuvant treatment, 175 with XRT, and 88 with SRS). Patients were less likely to receive adjuvant therapy if they were older than 75 years (odds ratio [OR] = 0.730; 95% confidence interval [CI], 0.548–0.973), female (OR = 0.731; 95% CI, 0.547–0.978), or unmarried (OR = 0.692; 95% CI, 0.515–0.929). Patients were more likely to receive adjuvant treatment for grade II/III tumors (OR = 5.586; 95% CI, 2.135–13.589), tumors over 5 cm (OR = 1.850; 95% CI, 1.332–2.567) or partial resection (OR = 3.230; 95% CI, 2.327–4.484). For those receiving adjuvant therapy, SRS was less likely than XRT in patients diagnosed with grade II/III tumors (OR = 0.061; 95% CI, 0.006–0.655) or a 1-unit increase in Gagne comorbidity score (OR = 0.761; 95% CI, 0.599–0.968). Yearly between 2000 and 2010, 10.65% to 19.77% of patients received adjuvant therapy (7.143%–42.105% of those who received SRS). Although no survival benefit was seen with the addition of adjuvant therapy (P = .1236), the subgroup of patients receiving SRS had better survival compared with those receiving surgery alone (adjusted hazard ratio [aHR] = 0.544; 95% CI, 0.318–0.929). Furthermore, when stratifying patients by degree of resection, those who underwent partial or local resection and did not receive SRS had an increased risk of death compared with those who did (aHR = 1.934; 95% CI, 0.992–3.771).

CONCLUSIONS: Utilization of adjuvant XRT and SRS remained stable between 2000 and 2010. Male sex, young age, marriage, partial resection, grade II/III tumors, and large tumors predicted for use of adjuvant therapy. For all patients, SRS improved survival compared with craniotomy alone. For patients with incomplete resection, SRS improved survival compared with craniotomy alone and adjuvant XRT. Randomized, prospective clinical trials are needed to better define the role of adjuvant XRT or SRS.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content